Use of Machine Learning and Artificial Intelligence to predict SARS CoV 2 infection from Full Blood Counts in a population
Abstract Since December 2019 the novel coronavirus SARS CoV 2 has been identified as the cause of the pandemic Covid 19. Early symptoms overlap with other common conditions such as common cold and Influenza, making early screening and diagnosis are crucial goals for health practitioners. The aim of the study was to use machine learning, an artificial neural network (ANN) and a simple statistical test to identify SARS CoV 2 positive patients from full blood counts without knowledge of symptoms or history of the individuals. The dataset included in the analysis and training contains anonymized full blood count results from patients seen at the Hospital Israelita Albert Einstein, at Sao Paulo, Brazil, and who had samples collected to perform the SARS CoV 2 rt PCR test during a visit to the hospital. Patient data was anonymised by the hospital, clinical data was standardized to have a mean of zero and a unit standard deviation. This data was made public with the aim to allow researchers to develop ways to enable the hospital to rapidly predict and potentially identify SARS CoV 2 positive patients. We find that with full blood counts random forest, shallow learning and a flexible ANN model predict SARS CoV 2 patients with high accuracy between populations on regular wards (AUC 93 94% and those not admitted to hospital or in the community (AUC 80 86% Here AUC is the Area Under the receiver operating characteristics Curve and a measure for model performance. Moreover, a simple linear combination of 4 blood counts can be used to have an AUC of 85% for patients within the community. The normalised data of different blood parameters from SARS CoV 2 positive patients exhibit a decrease in platelets, leukocytes, eosinophils, basophils and lymphocytes, and an increase in monocytes. SARS CoV 2 positive patients exhibit a characteristic immune response profile pattern and changes in different parameters measured in the full blood count that are detected from simple and rapid blood tests. While symptoms at an early stage of infection are known to overlap with other common conditions, parameters of the full blood count can be analysed to distinguish the viral type at an earlier stage than current rt PCR tests for SARS CoV 2 allow at present. This new methodology has potential to greatly improve initial screening for patients where PCR based diagnostic tools are limited.
International Immunopharmacology